NCT05243550 · OUTCOME
Number of Participants With Post-baseline PCS Chemistry Values
A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer · Source last updated 2026-05-11
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- COUNT_OF_PARTICIPANTS
- Unit
- Participants
- Interval / dispersion
- Not reported
- Time frame
- 6 months
What was measured
The number of patients with each type of event is summarized.
Analysis population: All patients who received any dose of UGN-102 and who had a post-baseline laboratory value.
Groups in this outcome
UGN-102
6 once-weekly intravesical instillations of UGN-102 (75 mg mitomycin).
Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.
Analysis denominator · Participants
| Group | Source count |
|---|
| UGN-102 | 240 |
|---|
Reported measurements
Alanine aminotransferase > 3 × ULN
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| UGN-102 | 1 | Not reported | Not reported | Not reported | Not reported |
|---|
Aspartate aminotransferase > 3 × ULN
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| UGN-102 | 1 | Not reported | Not reported | Not reported | Not reported |
|---|
Bilirubin > 1.5 × ULN
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| UGN-102 | 6 | Not reported | Not reported | Not reported | Not reported |
|---|
Creatinine > 194 μmol/L
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| UGN-102 | 8 | Not reported | Not reported | Not reported | Not reported |
|---|
Gamma glutamyl transferase > 2.5 × ULN
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| UGN-102 | 11 | Not reported | Not reported | Not reported | Not reported |
|---|
Potassium < 3.0 mmol/L
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| UGN-102 | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
Potassium > 5.5 mmol/L
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| UGN-102 | 20 | Not reported | Not reported | Not reported | Not reported |
|---|
Sodium ≤ 130 mmol/L
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| UGN-102 | 1 | Not reported | Not reported | Not reported | Not reported |
|---|
Sodium > 150 mmol/L
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| UGN-102 | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
Complete source fields
- classes
- title
- Alanine aminotransferase > 3 × ULN
- title
- Aspartate aminotransferase > 3 × ULN
- title
- Bilirubin > 1.5 × ULN
- title
- Creatinine > 194 μmol/L
- title
- Gamma glutamyl transferase > 2.5 × ULN
- title
- Potassium < 3.0 mmol/L
- title
- Potassium > 5.5 mmol/L
- title
- Sodium ≤ 130 mmol/L
- title
- Sodium > 150 mmol/L
- description
- The number of patients with each type of event is summarized.
- groups
- description
- 6 once-weekly intravesical instillations of UGN-102 (75 mg mitomycin).
- id
- OG000
- title
- UGN-102
- param Type
- COUNT_OF_PARTICIPANTS
- population Description
- All patients who received any dose of UGN-102 and who had a post-baseline laboratory value.
- reporting Status
- POSTED
- time Frame
- 6 months
- title
- Number of Participants With Post-baseline PCS Chemistry Values
- type
- SECONDARY
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice